Aelis Farma SA (AELIS.PA)

13.20 +0.10 (+0.76%) 收市：02:27PM CEST

Aelis Farma SA

146 rue Lafaurie de Monbadon
Bordeaux 33 000
France
33 5 54 54 23 27
https://www.aelisfarma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 26

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Pier Vincenzo Piazza M.D., Ph.D.	CEO & Director	473.61k	無	1961
Ms. Marie Line Lefevre	Head of Finance	無	無	無
Stephanie Monlezun	Chief Operating Officer	無	無	無
Ms. Lea Floquet	Head of Legal	無	無	無
Mr. Arsene Guekam	Chief Corporate Development Officer	無	無	無
Ms. Sandy Fabre	Head of Discovery & IP Leader	無	無	無
Ms. Aurelie Boucard	Head of Preclinical Development	無	無	無
Ms. Helle Mengel	Head of Clinical Development	無	無	無
Ms. Corinne Chaimbault	Head of Pharmaceutical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.

公司管治

截至 無 止，Aelis Farma SA 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。